Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with a reduction of oxidative stress and inflammation in patients with type 2 diabetes mellitus - von Bibra, H; Diamant, M; Scheffer, P G; Siegmund, T; Schumm-Draeger, P-M (Diabetes Vasc Dis Res, 2008)